Class IIFood
Outshine Fruit Bars Grape recall
Summary
Dreyer's Grand Ice Cream Inc. is recalling Outshine Fruit Bars Grape (food). According to the FDA report, the reason is: Foreign object: products may contain glass pieces. The FDA rated this a Class II: the product may cause temporary or medically reversible health problems; serious harm is unlikely. Recall status: Ongoing.
Details from the FDA report
- Product
- Outshine Fruit Bars Grape, 6-Count 2.5 ounce, with UPC 041548244044, packaged in paper outer cartons; individual fruit bars in plastic wrapper. Keep at 0F (-18C) or colder.
- Reason
- Foreign object: products may contain glass pieces
- Lot / code info
- Batch code/ Best Before (bottom of package): LLA616803 30 SEP 2027 LLA616903 30 SEP 2027 LLA619703 31 OCT 2027 UPC Bottom of package: 041548244044 LLA619803 31 OCT 2027 LLA619903 31 OCT 2027 LLA620003 31 OCT 2027 LLA620103 31 OCT 2027 LLA620203 31 OCT 2027 LLA620303 31 OCT 2027
- Quantity
- 281 pallets
- Distribution
- The adulterated product was distributed to the following States: AL, AR, AZ, CA,CO,CT, FL,GA, IA,ID, IL, KS, LA, MA,MD,MI, MN,MO, NC, ND, NH, NJ, NV, NY, OH, PA, PR, TN TX, UT, VA, VI, WA, and WI.
- Recalling company
- Dreyer's Grand Ice Cream Inc., Laurel, MD United States
- Recall started
- August 18, 2026
- FDA report date
- September 2, 2026
- Classification
- Class II: The product may cause temporary or medically reversible health problems; serious harm is unlikely.
- Voluntary / mandated
- Voluntary: Firm initiated
- Status
- Ongoing
- Recall number
- H-1266-2026
What to do
- Check whether you have this product, and compare the lot numbers, codes, or dates on your package with the codes listed above.
- If it matches, stop using it and keep it away from children and pets.
- Contact the recalling company (Dreyer's Grand Ice Cream Inc.) or the store where you bought it about returns or refunds.
- If you think the product made you or someone else sick, contact a doctor or pharmacist. In an emergency call 911.
- You can report problems to the FDA via MedWatch.